p53 Antibody (Pab DO-1) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-50538
Conjugate
Catalog #
Key Product Details
Validated by
Biological Validation
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Chromatin Immunoprecipitation (ChIP), Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Western Blot
Cited:
Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2A Clone # Pab DO-1
Format
BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Recombinant human wild type p53 protein expressed in E.coli
Specificity
DO-1 recognises wild-type and mutant p53. DO-1 recognises three of the p53 isoforms (p53, p53 beta, p53 gamma).
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Theoretical MW
53 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for p53 Antibody (Pab DO-1) - BSA Free
Western Blot: p53 Antibody (Pab DO-1)BSA Free [NBP2-50538]
Western Blot: p53 Antibody (Pab DO-1) [NBP2-50538] - B) Western Blot analyses of RPMI-8402 and NALM-6 cell lines treated for 24 h with AZD-1775 (185 nM) and PF-00477736 (25 and 250 nM respectively). B-actin was used for loading normalization. For relative quantification of each protein see Figure S3A and for whole western blot images see Figure S6. Image collected and cropped by CiteAb from the following publication (https://www.mdpi.com/2072-6694/11/11/1654) licensed under a CC-BY license.Western Blot: p53 Antibody (Pab DO-1) - BSA Free [NBP2-50538] -
Western Blot: p53 Antibody (Pab DO-1) - BSA Free [NBP2-50538] - DCQ reduces HIF-1 alpha through different mechanisms in MCF-7 & MDA-MB-231. (A) MCF-7 cells were transfected with siRNA against p53 & ctrl siRNA (scrambled sequence) using lipofectamine 2000. After 24 hours, cells were treated with DCQ (5 μM) for 6 hours under hypoxia. Whole cell lysates were prepared, & blots were probed against indicated antibodies. (B) MCF-7 cells were transfected with siRNA against p53 & ctrl siRNA (scrambled sequence) using lipofectamine 2000. Transfected cells were treated with DCQ (5 μM) for 6 hours under hypoxia. The extent of DNA fragmentation was determined by TUNEL assay 24 hours later using flow cytometry. One-way ANOVA was used to compare DCQ-treated versus control & statistical significance of p < 0.05 is indicated by *. (C) Whole cell lysates were prepared after pretreating MCF-7 & MDA-MB-231 with the proteasome inhibitor MG132 (3 μM) then treated with DCQ, & blots were probed for HIF-1 alpha. Results are from three independent experiments. (D) Whole cell lysates of MCF-7 were prepared after 6 hours of exposure to DCQ (5 μM) under normoxia or hypoxia, & blots were probed for p-AKT, mTOR, p-mTOR & GAPDH. Image collected & cropped by CiteAb from the following publication (https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-12), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Western Blot: p53 Antibody (Pab DO-1) - BSA Free [NBP2-50538] -
Western Blot: p53 Antibody (Pab DO-1) - BSA Free [NBP2-50538] - DCQ induces DNA damage & apoptosis via reactive oxygen species. (A) Whole cell lysates of MCF-7 & MDA-MB-231 were prepared after 6 hours of exposure to DCQ (5 μM) under normoxia or hypoxia, & blots were probed for p-H2AX, p53, p-p53, p21, HIF-1 alpha & GAPDH. Results are representative of three independent experiments. (B) MDA-MB-231 & MCF-7 cells were pretreated with 1 mM Vitamin E or DTT for 2 hours followed by 25 min incubation with 10 μM CM-H2DCFDA dye. Cells were washed with PBS & treated with DCQ for 1 hour under normoxia or hypoxia, after which cells were harvested & the amount of DCF fluorescence was analyzed by flow cytometry. Each percentage is the average ± SE of three independent experiments. (C) MDA-MB-231 & MCF-7 cells were pretreated with 1 mM Vitamin E or DTT for 2 hours followed by 6 hours treatment with DCQ under normoxia or hypoxia. After 24 hours, the extent of DNA fragmentation was determined by TUNEL assay & measured by flow cytometry. One-way ANOVA was used to compare DCQ-treated versus control & statistical significance of p < 0.05 is indicated by *. (D) Whole cell lysates of MCF-7 & MDA-MB-231 were prepared after 6 hours of exposure to DCQ (5 μM) under normoxia or hypoxia, & blots were probed for HIF-1 alpha & GAPDH. Results are representative of three independent experiments. Image collected & cropped by CiteAb from the following publication (https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-12), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Applications for p53 Antibody (Pab DO-1) - BSA Free
Application
Recommended Usage
Chromatin Immunoprecipitation (ChIP)
1:10-1:500
Immunohistochemistry
1:10 - 1:500
Immunoprecipitation
1:10 - 1:500
Western Blot
1:100 - 1:2000
Application Notes
Positive control(s): MDA-MB-231 cell line.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Format
BSA Free
Preservative
0.02% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: p53
Alternate Names
BCC7, LFS1, TP53, TRP53
Gene Symbol
TP53
Additional p53 Products
Product Documents for p53 Antibody (Pab DO-1) - BSA Free
Product Specific Notices for p53 Antibody (Pab DO-1) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...